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Abstract
Background: Protease inhibitors (PIs) have been associated with metabolic complications. There
is a trend to switch to simpler therapy to improve these disturbances. We report a case-series
describing the effects in metabolic abnormalities in seven HIV-infected children, previously treated
with protease inhibitor (PI) after switching to nevirapine.
Methods: Seven children with stable PI-containing regimen and a long lasting HIV-1 RNA < 50
copies/ml were switched to nevirapine. All patients were naïve to non nucleoside reverse
transcriptase inhibitor. PIs were switched to nevirapine. Preentry nucleoside reverse transcriptase
inhibitors were maintained. The substitution of PIs with nevirapine was made when the patient
showed hyperlipidemia or lipodystrophy or the physician and/or the patient's willingness to
simplify. Clinical, laboratory data and anthropometric parameters were assessed every 3 months.
Dual-energy X-Ray absorptiometry scans (DXA) was performed at baseline and at 12 months.
Results: Seven HIV-infected children were enrolled. Median age: 130 months (99,177). Median
baseline CD4%: 32%. All had HIV-1 RNA < 50 copies/ml. Median length of preentry PI-therapy was
47 months (28, 91). Median age at the beginning of nevirapine was 120 months (99,177). Median
decrease in cholesterol in 7.2 mmol/L was observed (P = 0.09), from baseline to 12 months. HDL-
cholesterol increased in 5.1 mmol/L (P = 0.03) throughout the study period. No significant changes
were observed in DXA with regard to body fat, but changes in total body bone mineral content
and lean body content were significant. CD4% remained stable. All patients but one maintained viral
load < 50 copies/ml at 12 months. The patient with virologic failure referred bad adherence.
Children referred to take medication more easily.
Conclusion: PI substitution with nevirapine improved lipid profile in our patients, although this
strategy did not show significant changes in body fat or lipodystrophy.
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Metabolic complications are prevalent in HIV-infected
children treated with highly active antiretroviral therapy
(HAART). Nowadays, lipodystrophy and osteopenia had
also been reported in HIV-infected children [[1-7], and
[8]]. Lipodystrophy syndrome is characterized by physical
and metabolic abnormalities including fat redistribution,
dyslipidemia and insulin resistance. Protease inhibitors
(PIs) have been associated with the development of these
events. This is one of the most important limiting factors
for long term therapy with HAART [[9-11], and [12]].
There is a trend to switch to simpler therapy including efa-
virenz, nevirapine, abacavir or atazanavir-containing regi-
men that might maintain viral suppression and improve
metabolic disturbances [13,14]. In adults, there are
reports demonstrating that the replacement of PI by nevi-
rapine might improve lipid abnormalities [[15-18], and
[19]]. There are few studies documenting these strategies
in children. In our case-series, we describe the possible
effects in metabolic abnormalities, including lipid profile,
lipodystrophy (LD) and bone mineral density (BMD) in
seven HIV-infected children, previously treated with PI
after switching to nevirapine and with a high level of viral
suppression for a long period of time (at least 6 months).
Methods
Children's regimens were changed if they fulfilled these
criteria: all were older than 12 months; they were receiv-
ing a stable PI-containing regimen (2 nucleoside reverse
transcriptase inhibitor (NRTI) plus 1 or 2 PIs) for at least
6 consecutive months; they were naive to non nucleoside
reverse transcriptase inhibitor (NNRTI). All patients had
plasma HIV-1 RNA viral load < 50 copies/ml at baseline
and for a median of 6 months before study entry and a sta-
ble clinical and immunological situation. Then, PIs were
switched to nevirapine and preentry NRTI were main-
tained. The substitution of PIs with nevirapine was made
if the patient showed hyperlipidemia and/or lipodystro-
phy or if the physician or the family wanted to simplify
the antiretroviral regimen. Hyperlipidemia was consid-
ered if cholesterol was ≥ 6.5 mmol/L and/or LDL-choles-
terol was ≥ 4 mmol/L and/or triglycerides were ≥ 5.5
mmol/L. Glucose metabolism was evaluated and was con-
sidered abnormal if fasting glucose was between 100 mg/
dl and 126 mg/dl. Insulin levels and C-peptide were also
performed and were considered abnormal if insulin was >
15 UI/ml and C-peptide was > 2 ng/ml. Lipodystrophy
was diagnosed if patients presented at least one of the fol-
lowing features: peripheral loss of adipose tissue: sunken
cheeks, thinning extremities, hips or buttocks (lipoatro-
phy), central gain in adiposity: dorsocervical and/or abdo-
men fat accumulation (lipohypertrophy) or both features
(mixed syndrome).
Children were excluded if they suffered from hepatitis C
virus infection or if they showed aminotransferases eleva-
tions or if they were receiving lipid-lowering drugs. Stand-
ard clinical and laboratory data were performed every 3
months. Laboratory data included: CD4 cell count,
plasma HIV-1 RNA viral load (using Amplicor HIV moni-
tor Roche, range 50–500.000 copies/ml), blood counts
and blood chemistries (glucose, AST, calcium, phospho-
rus, amylase, lipase, creatinine kinase, etc). All data were
obtained after 8–12 hours of fasting. No dietary or exer-
cise history was recorded.
Metabolic evaluation and anthropometric measurements
were performed every 6 months including C-peptide,
insulin, lipid profile, body weight, height, mid-arm cir-
cumference, triceps and subescapular skin folds. Skin
folds were measured using a manual trackball. Body
weight was measured on a balance beam scale, and height
was measured using the same wall-mounted stadiometer.
Measurements were performed by the same person. Dual-
energy X-Ray absorptiometry scans (DXA) was used to
estimate whole-body composition. The same scanner
(Norland XR-26HS densitometer) was used for evalua-
tions on any patient. The entire body was scanned. Varia-
bles analysed including: bone mineral density (BMD),
expressed in g/cm2, lean body mass (LBM) expressed in
grams and body fat expressed in grams and as a percentage
of total body weight. All compartments were analysed in
the arms, trunk, legs and face. Z score for lumbar BMD
and BMC-age related changes were estimated based on
Zachetta's report [20]. In this study, parameters were gen-
erated from data of 778 Argentine Caucasian children
(345 boys and 443 girls between 2 to 20 years old). Oste-
openia was defined as a Z score less than -1 for lumbar
spine, and osteoporosis when it was less than -2.5, follow-
ing WHO criteria [21]. Puberty stage of patients was
defined according to Tanner criteria [22]. Adherence, dif-
ficulty in taking medication and quality of life were
assessed by patient and/or caregiver's self report.
The statistical software Staview Mc Intosh was used.
Quantitative data were expressed in terms of means and
range. Qualitative variables were expressed as percentages.
Wilcoxon rank sum test for continuous data was used to
determinate changes over time and statistical significance.
P < 0.05 were considered statistically significant.
Written consent was obtained from six of the patients.
Results
Seven patients were enrolled (2 girls and 5 boys), median
age was 120 months (99,177). All were Caucasians. Six
children acquired infection by vertical transmission. One
girl had HIV infection of unknown origin. At baseline,
median CD4 percentage was 33%(29–42) and all hadPage 2 of 7
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months before. Related to CDC category, 2 patients were
on A1, 2 on C3, 2 on B2 and one on A3. At the beginning
of the follow up, 4 children were prepuberal. A girl
reached stage IV at 12 years. Other 2 patients reached Tan-
ner stage II. (Table 1) Five subjects who were born before
preHAART-era had been pre-treated with NRTI as mono-
therapy or dualtherapy and when PIs were available were
changed to HAART and 2 patients had received a PI-con-
taining regimen as a first line therapy. All were naive to
NNRTI. Median age at the beginning of first ARV therapy
was: 53 months (6,119) and median age at the beginning
of PIs was: 83 months (54,123). PIs used at study entry
were: indinavir (3 cases), amprenavir (2 cases), ritonavir
(2 cases, one was on ritonavir plus amprenavir and
another was on ritonavir alone), only one was on nelfina-
vir. The cumulative duration of previous PI before nevi-
rapine was: 44 months (28, 60) and the cumulative
duration of mono/dualteraphy with NRTI previous PI was
52 months (0,109). (Table 2)
The substitution of PIs with nevirapine was made due to
hyperlipidemia in 3 cases, the physician or the family
wanted to simplify the patient' regimen in 3 cases and
lipodystrophy in 1 case.
No acquired immunodeficiency syndrome-defining
events were reported. No rash or aminotransferases
changes occurred during this period. Only 1 patient
referred mild headache at the beginning of nevirapine-
containing regimen but it disappeared without discontin-
uing therapy. She had a prior diagnosis of migraine. Six of
seven patients maintained virologic control successfully,
with less than 50 copies/ml at all time points. One child
showed an increase in viral load up to10.325 copies/ml at
12 months. He referred bad adherence. Median CD4%
remained stable in all patients, from 33% (29, 42) at base-
line to 37% (27, 44) at 12 months, (P = 0.7).
At the beginning, cholesterol was ≥ 6.5 mmol/l in 3
patients, LDL-cholesterol was ≥ 4 mmol/l in 3/6 patients
and HDL-cholesterol was ≤ 1.16 mmol/l in 4/6 patients.
At study entry, in all patients, triglyceride levels, fasting
glucose, insulin, C-peptide, amylase or lipase were normal
and did not change throughout the study period (Table
3). Median decrease in total cholesterol from baseline to
12 months was 0.7 mmol/ml (P = 0.09) and median
increase in HDL-cholesterol was 0.5 mmol/ml from base-
line to the end of the study (P = 0.03). No significant
changes in LDL-cholesterol was observed. DXA was per-
formed in six patients, at the study entry and in all
patients at the study end. In these 6 patients, TBMC and
LMB tended to increase at 12 months. About body fat
changes, one girl and a boy showed a decrease in body fat
and fat percentage. In another boy, there was a decrease in
body fat percentage but no in total body fat. These 3
patients had also osteopenia and they were older than the
rest (median age: 13 years). Therefore, TBMC and LBM,
showed a significant increase (P = 0.04 and P = 0.02), but
no significant changes in fat (grams or %), Z score or
BMC-age related changes were founded. At baseline, one
patient showed osteoporosis (Z score: -4.21) and 2 osteo-
penia (Z scores: -1.05 and -1.14). In 3 cases Z score were
> 1 (Table 4).
With regard to anthropometric measurements, only
weight, height and mid-arm circumference showed a sig-
nificant increase (P = 0.01, P = 0.02, P = 0.02), (data not
shown). Lipodystrophy was clinically detected at the
beginning in 2 patients, one subject showed clinical signs
of peripheral lipoatrophy and another patient had central
lipohypertrophy. At 12 months, there were no changes in
patients with lipoatrophy, but there was a decrease in
abdominal fat accumulation in the patient with central
hypertrophy, this child were receiving indinavir before
changing.
Patients were asked about compliance and difficulty in
taking medication. All of them referred a sense of less dif-
ficulty in taking nevirapine compared with the PI-regi-
men.
Table 1: Baseline characteristics
PATIENT TRANSMISSION GENDER Age(years+months) CATEGORY(CDC) TANNER * LIPODYSTROPHY
1 UNKNOWN GIRL 13 Y 7 M A1 III to V no
2 VERTICAL BOY 9 Y 10 M A3 I-I no
3 VERTICAL BOY 8 Y 3 M A1 I-I no
4 VERTICAL GIRL 9 Y 2 M C3 I-I no
5 VERTICAL BOY 10 Y C3 I-I no
6 VERTICAL BOY 14 Y 7 M B2 II-III lipoatrohy
7 VERTICAL BOY 8 Y 2 M B2 II-III lipohypertrophy
MEDIAN 133(99,177)
* Puberty stage. Tanner JM. Grow and adolescence (2aedition) Oxford. Blackwell Scientific publication. 1962Page 3 of 7
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Patient 1
A 13-year-old girl who was receiving d4T + 3TC + ampre-
navir boosted with ritonavir was simplified to d4T + 3TC
+ nevirapine because she suffered from hypercholestero-
lemia. A decrease in total cholesterol, LDL cholesterol and
triglycerides was observed. She remained with VL < 50
copies/ml but her lumbar BMD Z score showed a decrease
from -1.05 to -3.34.
Patient 2
A 9-year-old girl who was receiving d4T + 3TC + amprena-
vir was simplified to d4T + 3TC + nevirapine because she
wanted to do her regimen easier to take. She referred that
she was happier after this change. She remained with
undetectable viral load. She did not show osteopenia
along the follow up.
Patient 3
An 8-year-old-boy who was receiving ZDV + ddI + ritona-
vir was simplified to ZDV + ddI + nevirapine because he
suffered from hypercholesterolemia. A light decrease in
total cholesterol was observed but not in LDL-cholesterol.
He remained with undetectable viral load and without
osteopenia.
Table 2: Antiretroviral therapy prior to nevirapine-containing regimen
PATIENT AGE at 1st 
regimen




CD4% Viral load cop/
ml
months NRTI NRTI NRTI PI PI 0–12 months 0–12 months
D4T-3TC- AMP(36 m)+
1 119 NO ZDV-DDI 27 AMP+RIT RIT (6 m) 33–41 50–50
2 39 NO ZDV-DDI 36 D4T-3TC-
AMP
AMP(48 m) 32–30 50–50
3 65 NO NO 0 ZDV-DDI-RIT RIT(32 m) 29–34 50–50
4 14 ZDV ZDV-DDI 19+21 D4T-3TC-NFV NFV(56 m) 42–44 50–50
5 92 NO NO 0 ZDV-ABC-
IND
IND(28 m) 34–30 50–50
6 9 ZDV/DDI NO 109 ZDV-DDI-IND IND(60 m) 32–27 50–10325
7 6 ZDV NO 92 ZDV-3TC-
IND
IND(52 m) 31–34 50–50
33%(29,42)
median 53 m (6,119) 52 m (0,109) 130 m (99,177) 47 m (28,60) 37%(27,44) 50
NRTI: nucleoside reverse transcriptase inhibitor, ZDV: zidovudine, DDI: dianosine, D4T: stavudine, 3TC: lamivudine; PI: protease inhibitor, AMP: 
amprenavir, RIT: ritonavir, NFV: nefinavir, IND: indinavir; m: months; cop/ml: copies/ml (HIV-RNA, liner range: 50–500.000 cop/ml)
Table 3: Metabolic parameters and lipid profile at baseline and at 12 months
PATIENT CHOLESTEROL HDL-cho LDL-cho TG GLUCOSE INSULIN C-PEPTIDE
(mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (IU/ml) (ng/ml)
Values 0–12 m 0–12 m 0–12 m 0–12 m 0–12 m 0–12 m 0–12 m
1 250–182 40–47 179–127 155–36 99–97 8,9–8,4 1,1–1,6
2 192–200 NA – 65 NA – 126 70–41 91–84 4,8–5,2 0,8–1,93
3 338–245 63–69 112–160 112–59 86–94 4,6-NA 0,74-NA
4 325–290 56–61 250–193 92–177 85–86 9,6–8,9 1,8-NA
5 188–152 32–48 133–93 116–92 88–88 9,8–19,4 0,5–0,4
6 120–101 37–35 71–60 60–29 75–78 10–12,3 2,2–1,3
7 195–220 45–52 126–150 118–86 81–85 10–6,9 1,1–1,4
median at baseline 195(120,338) 45(32,63) 129(71,250) 74(60,92) 86(75,99) 9,6(4,6–10) 1,3(0,5–2,5)
median at 12 m 200(101,290) 52(35,69) 127(60,193) 74(29,177) 87(78,97) 8,6(5,2–19,9) 1,4(0,4–1,93
P 0,09 0,04 0,34 0,17 0,4 0,9 0,9
Evolution after switching.
HDL-cho: HDL-cholesterol, LDL-cho: LDL-cholesterol, TG: triglycerides
To convert cholesterol from mg/dl to mmol/l, multiply by 0.0259
To convert triglycerides from mg/dl to mmol/l, multiply by 0.0113
To convert insulin from IU/ml to pmol/l, multiply by 7.175
To convert C-peptide from ng/ml to nmol/l, multiply by 0.33
To convert glucose from mg/dl to mmol/l, multiply by 0.0555Page 4 of 7
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A 9-year-old girl who was receiving d4T + 3TC + nelfinavir
was simplified to d4T + 3TC + nevirapine because she suf-
fered from hypercholesterolemia. A decrease in total cho-
lesterol and in LDL-cholesterol was observed. She showed
undetectable viral load at 12 months and the osteopenia
remained.
Patient 5
A 10-year-old boy who was receiving d4T + abacavir +
indinavir was simplified to d4T + abacavir + nevirapine
because he wanted to do his regimen easier to take and to
avoid renal damage associated to indinavir.
Patient 6
A 14 year-old adolescent who was receiving ZDV + ddI +
indinavir was simplified to ZDV + ddI + nevirapine
because he wanted to do his regimen easier to take and to
avoid renal damage associated to indinavir. At 12 months
he showed a decrease in total cholesterol and LDL-choles-
terol but had detectable viral load because of bad adher-
ence. He suffered from facial lipoatrophy and it remained
without changes after the substitution (we have to take
into account that NRTIs were not removed and these
drugs are implied in fat distribution).
Patient 7
An 8-year-old boy who was receiving ZDV + 3TC + indina-
vir was simplified to ZDV + 3TC + nevirapine because he
wanted to do his regimen easier to take, to avoid renal
damage associated to indinavir and to improve his
abdominal lipohypertrophy. He showed an important
decrease in abdominal fat accumulation at the end of the
year. His viral load remained undetectable.
Discussion
We report seven cases in which the substitution of PIs
(indinavir, saquinavir and nelfinavir) with nevirapine
resulted in a mild improve in total cholesterol and HDL-
cholesterol. Virological maintenance was achieved in all
patients but one during the 12 months. The patients that
showed virological failure at 12 month referred bad
adherence although the child's adherence at baseline was
considered good and the new regimen was less complex.
Nevertheless, all children maintained CD4 cell count and
good clinical and growth parameters.
PIs may have a strong association with dyslipidemia
[[2,3,5,9-12], and [23]]. There have been few studies in
children to evaluate the substitution of PI with NNRTI. Mc
Comsey et al reported a simplification trial in which the
PI was switched to efavirenz in children who had previ-
ously undetectable viral load for more than 6 months.
They showed maintenance of virologic suppression in all
patients who received the new regimen. A significant
improvement in lipid profile was also observed including
fasting total cholesterol, LDL-cholesterol, triglycerides
and total cholesterol: HDL-cholesterol ratio. The shift to a
simplified 3-NRTI regimen, including abacavir, in chil-
dren previously treated with PI-based HAART was
reported by Castelli-Gattinara et al. In this study the new
regimen allowed to maintain an immunological and viro-
logical control after 108 weeks with significant improve-
ment of dyslipidemia, including total-cholesterol, LDL-
cholesterol and triglycerides [24]. In our cases, we have
only seen a significant improvement in HDL-cholesterol
and a decrease in total cholesterol although this change
has not been significant. We must take into account that 3
patients had been also receiving stavudine, which might
be involved in dyslipidemia [25]. So, an improvement in
lipid profiles have been reported when stavudine was
replaced with abacavir or zidovudine in some studies. In
addition, substitution of stavudine with ZDV or a non-
thymidine analogue might lead to an improvement in
body fat as several studies have reported [[26,27], and
[28]]. Therefore, the substitution of stavudine in these
children could lead to reach a better control of lipid
metabolism. Additional factors that could have played a
roll include diet and exercise. A low fat diet and aerobic
exercise were advised at each visit, but they were not
recorded [29].













1 0,798–0.949 26.778–29.9807 13.082–12.249 31–28 -1.05 → -3.34 90.9–83.4
2 0,731–0,748 17.687–19.909 8071–10.922 30–34 2,08 → 4,31 116,9–135
3 0,759–0,832 20.751–23.293 9579–11.409 30–31 1,8 → 2,59 116,6–121,9
4 0,803–0,868 26.856–41.913 7014–5526 20-11 -4,21 → -3,01 70,1–82,1
5 0,687–0,723 19.300–20.563 7181–7949 26–27 1,01 → 0,88 110,5–110,4
6 0,76–0,83 22.559–28.061 10.967–11.393 31-28 -1,14 → -1,25 90–89,5
7 NA-0,732 NA-21.263 NA-13.069 NA-36 NA → 1,56 NA-112,8
P 0,04 0,02 0,2 0,8 0,2 0,2
BMC: bone mineral content, LMB: lean body mass, NA: not available, g: grams.Page 5 of 7
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insulin resistance and an improvement in insulin sensitiv-
ity has been observed in some studies when PIs were
switch to NNRTI or abacavir [13,30]. In our series, none
of the patients had insulin or glucose abnormalities at
baseline and there were not changes in these parameters
throughout the study period.
With regard to anthropometric measurements, there was
an increase in weight, height and in all the skin folds from
baseline to 12 months in all patients. Nevertheless, only
the increases in weight, height and mild-arm circumfer-
ence were significant. These changes could have been due
to normal growth in these children, one of the parameter
that we are not able to evaluate due to lack of a control
arm.
About DXA follow up, significant changes in TBMC, LBM
have been observed, but no in fat content. Therefore, in all
patients there was an increase in TBMC and LMB and
there was a decrease in total fat in 3 children, but changes
were not significative and all gained weight with regard to
baseline. Lumbar BMD Z score and BMC – age related
changes did not change significantly during the study
period.
Physical examinations did not show a clinical improve-
ment in lipoatrophy. This was expected due to the contin-
uous use of zidovudine plus didanosine in this boy. In
one patient a decrease in central obesity was observed. He
had been receiving Indinavir before nevirapine-regimen
and this PI had been associated to central lipohypertropy
[31]. These changes may be related to growth or puberty
(an increase or decrease in fat or an increase in BMC and
LBM should be expected during growth) or to antiretrovi-
ral itself. A control group of children maintained with the
same ARV regimen including PI would be necessary to
determinate the individual impact of nevirapine substitu-
tion on these parameters.
Although adherence questionnaires were not performed,
our patients referred a feeling of an easier to take medica-
tion and all their new regimens contained fewer pills than
the previous therapy.
This case-series includes only seven patients and 12
months may not be sufficient for a correct follow up to
detect significant changes in lipid and mainly in anthro-
pometrics parameters, specially in children and adoles-
cents, who are experimenting continuous changes in body
composition and therefore, the observed changes in these
cases could be related to others factors like growth,
puberty and normal physical development. Therefore,
this strategy could be an option in selected children but
more studies are necessary.
Conclusion
The substitution of PI with nevirapine may be an option
in selected HIV-infected children that might lead to
improvement in some lipid abnormalities as other studies
have showed [3,13-17].
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